Articles

Find an Article

Filter articles

Showing 1 to 10 of 691 results

How patents for transgenic mice got caught in a sufficiency trap

16-07-2020David Fyfield

As the UK Supreme Court reverses a Court of Appeal decision relating to sufficiency, the ruling leaves patent applicants in a potentially difficult position, argues David Fyfield of Charles Russell Speechlys.

No SPC crown for Royalty Pharma

Germany10-07-2020Joel Beevers and Michael Pears

An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.

Could good intentions lead to future danger?

US10-07-2020MaryAnne Armstrong

The rush to open access to IP-protected tech, medicines and devices in the fight against COVID-19 could cause problems later, argues MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch.

Five core IP legal principles in life sciences

09-07-2020Jonathan Harris, Ian Lodovice, and Nisan Zaghi

In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen.

Trade secrets: an alternative for life sciences IP?

09-07-2020John Stone

Amid confusion over patent eligibility, US life sciences IP owners should consider trade secret law when building their IP protection strategy, argues John A Stone of DeCotiis, FitzPatrick, Cole & Giblin.

EPO’s G3/19: no turning back?

Germany02-07-2020Anna Gregson

The EPO’s May 2020 decision in G3/19, on the patentability of certain plants, was among the most controversial in the office’s history. Anna Gregson of Mathys & Squire explores the implications.

Analysis: Kymab’s ‘patent bargain’ clarification and why it matters

UK25-06-2020Sarah Morgan

Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers. 

SPCs: a deep dive into CJEU case law

23-06-2020Katie Cambrook and Ben Millson

The CJEU’s many attempts to clarify the law around SPCs has created more questions than answers, as Katie Cambrook and Ben Millson of Bristows explain.

Lanham Act: brand owners’ current weapon of choice

11-06-2020

As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Showing 1 to 10 of 691 results

LSIPR